
==== Front
Sao Paulo Med J
Sao Paulo Med J
Sao Paulo Med J
São Paulo Medical Journal
1516-3180
1806-9460
Associação Paulista de Medicina - APM

17119698
10.1590/S1516-31802006000300014
Review Article
Parkinson's disease and dopamine transporter neuroimaging – a critical review
Doença de Parkinson e neuroimagem do transportador de dopamina – uma revisão críticaShih Ming Chi *
Hoexter Marcelo Queiroz *
de Andrade Luiz Augusto Franco *
Bressan Rodrigo Affonseca *
Address for correspondence: Ming Chi Shih Rodrigo Affonseca Bressan LiNC - Laboratório Interdisciplinar de Neuroimagem e Cognição, Departamento de Psiquiatria Universidade Federal de São Paulo Rua Dr. Bacelar, 334 São Paulo (SP) — Brasil – CEP 04026-001 Tel. (+55 11) 5084-7060 Fax. (+55 11) 5084-7061 E-mail: mingchi@psiquiatria.epm.br E-mail: r.bressan@iop.kcl.ac.uk
Conflict of interest: Not declared

04 5 2006
2006
124 3 168175
28 7 2005
29 5 2006
30 5 2006
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons license.
ABSTRACT

Parkinson's disease (PD) is a common neuro-degenerative disorder that is mainly caused by dopaminergic neuron loss in the substantia nigra. Several nuclear medicine radiotracers have been developed to evaluate PD diagnoses and disease evolution in vivo in PD patients. Positron emission tomography (PET) and single photon computerized emission tomography (SPECT) radiotracers for the dopamine transporter (DAT) provide good markers for the integrity of the presynaptic dopaminergic system affected in PD. Over the last decade, radiotracers suitable for imaging the DAT have been the subject of most efforts. In this review, we provide a critical discussion on the utility of DAT imaging for Parkinson's disease diagnosis (sensitivity and specificity).

RESUMO

A doença de Parkinson (DP) é uma desordem neurodegenerativa causada por perda de neurônios dopaminérgicos na substância negra. Vários traçadores da medicina nuclear têm sido desenvolvidos para avaliar o diagnóstico e acompanhamento da DP. Traçadores para o transportador de dopamina (TDA) utilizados na tomografia por emissão de pósitrons (PET) e tomografia por emissão de fóton único (SPECT) demonstram boa marcação na integridade de sistema dopaminergico pré-sináptico, afetada na DP. Na última década, radiotraçadores apropriados para imagens de TDA têm sido mais estudados. Nesta revisão, provemos uma discussão crítica sobre a utilidade dessas imagens de TDA para o diagnóstico de DP (sensibilidade e especificidade).

KEY WORDS:

Parkinson disease
Dopamine
Emission-computed tomography
Single-photon emission-computerized tomography
Diagnosis
PALAVRAS-CHAVE:

Doença de Parkinson
Dopamina
Tomografia computadorizada de emissão
Tomografia computadorizada de emissão de fóton único
Diagnóstico
==== Body
pmcINTRODUCTION

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the presence of Lewy bodies and progressive degeneration of dopaminergic neurons in the substantia nigra, with loss of their nerve terminals in the basal ganglia structures, especially in the striatum.1 Other etiopathogenic processes are suspected to incite and perpetuate PD, such as oxidative stress, mitochondrial dysfunction, proteasome dysfunction and protein aggregation, which can lead to nigrostriatal cell dysfunction and death.2

The overall prevalence of PD is estimated at 0.2% but rises with increasing age, affecting as many as 0.5-1% of individuals aged 65-69 years and as many as 1-3% of individuals older than 80 years.3 PD diagnosis is substantially based on clinical symptoms and is characterized by resting tremor, rigidity, bradykinesia, and postural instability, and also favorable response to levodopa therapy,1,4 but few researchers have attempted to develop rigorous diagnostic criteria that can be applied consistently and assessed for reliability.1

To address the problem of identifying Parkinson's disease in its initial phases of clinical expression, three levels of diagnostic confidence have been differentiated: definite, probable and possible.1,5 The diagnoses of possible and probable PD are based on clinical criteria alone, whereas the presence of Lewy bodies in histopathological findings is required for definite PD diagnosis. However, Lewy bodies are also present in many other diseases6,7 and are probably absent in autosomal recessive juvenile Parkinsonism,8 which makes these diagnostic criteria not totally satisfactory.9

In clinical-pathological studies, up to 25% of cases with an antemortem clinical diagnosis of PD were found not to have PD at postmortem examination.1,10 Parkinson's disease patients manifest symptoms only when 50 to 80% of the nigrostriatal neurons are lost. Clinical diagnosis fails to identify individuals before they reach such a significant loss of dopamine neurons. Such individuals would benefit from early diagnosis, before dopamine loss is too severe, with the aim of attempting to implement the neuroprotective interventions that have been developed recently. Thus, improvement in the accuracy of clinical diagnoses of PD is needed for epidemiological studies and practical clinical treatment.1,11

In this review, we discuss the relationship between the dopamine system, especially the dopamine transporter (DAT), and Parkinson's disease (PD). We also discuss the usefulness of DAT neuroimaging using positron emission tomography (PET) and single photon emission computerized tomography (SPECT) for PD diagnosis and follow-up.

Molecular imaging Molecular imaging

Conventional high-resolution imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) are not so useful for PD diagnosis. These techniques do, however, have a role in the differential diagnosis with some other types of Parkinsonism. Researchers have been interested in developing sensitive diagnostic techniques for early PD by assessing DAT concentrations in the striatum. The key to molecular imaging in nuclear medicine is radiotracers: substances that have high affinity and specificity to a receptor site that is labeled with a radioisotope. These radioligands allow in vivo evaluation of receptor density and affinity, measured as binding potential.12 The tracers are labeled with [123I] and [99mTc] for SPECT, or isotopes [11C], [18F], [15O] and [13N] for PET. Although PET provides higher resolution and better physical quantitative capacity than SPECT, PET is less practical as a routine procedure because of its high cost and the shorter half-life of its radiotracers. On the other hand, SPECT uses isotopes with longer half-lives that can be stored on site.

Over the last decade, radiotracers suitable for DAT imaging have been the subject of great investigative efforts. Several DAT ligands have been successfully used as methods for evaluating neuronal loss, for PD diagnosis.11,13–19 For this reason, DAT ligands have become well-established markers that are useful for evaluating changes in presynaptic DAT sites in vivo and in vitro.

Dopamine transporter (DAT)

Dopamine transporter (DAT) was first described 30 years ago. It is an 80-kDa protein composed of 12 transmembrane spanning regions with the carboxyl and amino termini residing intracellularly.20 The protein is externally glycosylated and is localized in the axonal membranes of nigrostriatal dopaminergic neurons.21 The human DAT gene is localized on chromosome 5p15.3.22–24 DAT is located on the plasma membrane of nerve terminals in a small number of neurons in the brain, especially in the striatum and nucleus accumbens, but also in the globus pallidus, cingulate cortex, olfactory tubercle, amygdala and midbrain.25 DAT regulates the dopamine concentration in the synaptic cleft through reuptake of dopamine into presynaptic neurons; it plays a central role in the spatial and temporal buffering of the released dopamine.26 Its activity can be regulated by presynaptic receptors, protein kinases, and membrane trafficking.27–29 DAT exerts vital influence on dopamine function, by modulating locomotor activity, cognition and the reward system.30 Pharmacologically, DAT serves as the binding site for drugs of abuse31 (e.g. cocaine and amphetamine) and therapeutic agents32 (e.g. methylphenidate and bupropion). It has been observed that striatal DAT declines at a rate of approximately 6-7% per decade in the human striatum.33–35 The density of DAT can be used as a marker for dopamine terminal innervation.36

DAT neuroimaging

Postmortem studies have shown an association between PD and striatal DAT concentration.37,38 Evaluation of DAT in human postmortem tissue has demonstrated good correlation of in vitro tracers such as [125I] altropane and DAT reduction in PD.39 DAT provides a good site for monitoring the integrity of the presynaptic dopaminergic systems that are most affected in PD. Several DAT agents have been developed for diagnosing PD and monitoring the treatment of PD patients, based on DAT antagonists such as methylphenidate and cocaine (tropane derivatives).18,40,41 Cocaine analogs (WIN35428) and their derivatives gain potency through halogenation of their phenyl rings. On the other hand, lack of ester linkages between tropane and phenyl moiety sites is the main mechanism for cocaine inactivation and degradation. Table 1 summarizes the DAT radiotracers that have reached phase III or IV of clinical applications, including [11C] cocaine, [123I] β-CIT (2b-carboxymethoxy-3b-[4-iodophenyl] tropane), [123I] FE-CIT (ioflupane), [123I]/[18F]/[11C] FP-CIT (N-[3-fluoropropyl]-2ss-carbomethoxy-3ss[4-iodophenyl]nortropane), [18F]/[11C] CFT (2beta-carbomethoxy-3betafluorophenyl-tro-pane), [123I]/[11C] altropane, [123I]/[11C] PE2I (N-{3-iodoprop-(2E)-enyl}-2beta-carboxymethoxy-3beta-{4'methylphenyl} nortropane), and [11C] methylphenidate.

Table 1. Dopamine transporter radiotracers according to the literature

Tracer	Isotope	Scan time (min.)	Peak striatal activity (min.)	Signal to noise ratio	SERT: DAT	PET/SPECT	References	
Cocaine	[11C]	10-20	4-7	< 2	Almost equal affinity	PET	Ritz et al., 199045
Logan et al., 199046
Telang et al., 199947	
CFT	[11C]	60-90	225	5	>12-fold Ki
12.6	PET	Frost et al., 199313
Rinne et al., 199948,49
Madras et al., l98950
Morris et al., 199651
Haaparanta et al., 199652
Brownell et al., 199653	
CFT	[l8F]	120	225	10	4-l6 DAT:SERT	PET	Haaparanta et al., 199652	
WIN 35,428	[3H]	NA	NA	NA	NA	PET	Gatley et al., 199554	
β-CIT or RTI 55 dopa scan	[123I]	1440	900-1200	9	1.6	SPECT	Innis et al., 199319
Laruelle et al., 199455
Brucke et al., 199356
Laruelle et al, 199457	
FE or FP-CIT	[123I]
[11C]
[18F]	70-240	30	8	Same β-CIT	PET: SPECT	Kuikka et al., 199558
Antonini et al., 200159
Tissing et al, 199860
Booij et al., 200161
Lundkvist et al., 199762
Chaly et al., 199663
Abi-Dargham et al., 199664	
Altropane	[123I]
[11C]	60-1 20	10-15	~6	25-fold DAT.
Sert selectivity
Ki 6.8	SPECT PET	Madras et al, 199839,65,66
Fischman et al., 199867
Elmaleh et al., 199668	
PE2I or RTI-32	[123I]	8 -70	~70	8	high affinity (Ki =17 nM) and selectivity for DAT	SPECT PET	Emond et al., 199769
Chalon et al., 199970
Hall et al., 199971
Guilloteau et al., 199872
Poyot et al., 200173
Kuikka et al., 199974
Repo et al., 199975	
TRODAT-1	[99mTc]	240	180-240	2.5	Ki = l2 nM	SPECT	Choi et al., 199976
Acton et al., 199977
Kao et al., 200178	
D-threo-methylphenidate	[11C]	30	15	2-3	Ki = 12 nM
DAT	PET	Gatley et al., 199554
Volkow et al., 199532
Lee et al., 200079	
CFT = 2beta-carbomethoxy-3betafluorophenyl-tropane;WIN = [11C]2beta-carbomethoxy-3beta-(4-fluorophenyl)-tropane; β-CIT = 2b-carboxymethoxy3b-[4-iodophenyl] tropane; RTI = [1R-(exo,exo)]- 3-[4-(iodo123)phenyl]-8-methyl-8-azabicyclo[3.2.1]o ctane-2-carb oxylic acid methyl ester; FE-CIT = ioflupane; FP-CIT = N-[3-fluoropropyl]-2ss-carbomethoxy-3ss-[4-iodophenyl]nortropane; PE2I = N-{3-iodoprop-(2E)-enyl}-2beta-carboxymethoxy-3beta-{4'methylphenyl}nortropane; RTI-32 = methyl (1R-2-exo-3-exo)-8-methyl-3-(4-methylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate; TRODAT-1 = [2-[[2-[[[3-(4-chloro- phenyl)-8-methyl-8-azabicyclo[3, 2, 1]oct-2-yl]methyl] (2-mercaptoethyl)amino]ethyl]amino]ethanethiolato(3)]-oxo-[1R-(exo -exo)]; NA = not available; DAT = dopamine transporter; SERT = serotonin transporter; PET = photon emission tomography; SPECT = single photon emission computerized tomography.

Previous molecular imaging approaches with [18F] dopa and PET labeling for dopadecarboxylase (the enzyme involved in dopa-mine synthesis) was considered to be the gold standard for evaluating nigral dopaminergic neurons in PD42,43 before the advent of DAT tracers. Tropane derivative studies ([11C] CFT and [123I] β-CIT) have shown a direct correlation between decreased DAT in the putamen and PD symptoms.13,44 Descriptions of the characteristics of several DAT tracers, including time to reach tracer equilibrium (scan time); tracer maximum accumulation (peak striatal activity); differential contrast imaging in the striatal area and the rest of the brain, especially in the cerebellum (signal to noise ratio); and affinity competition inhibition of serotonin and dopamine transporters (SERT: DAT) are given in Table 1.13,19,32,39,45–79

DAT quantification technique

Region-of-interest (ROI) semi-quantitative evaluation techniques have to be used to assess specific DAT binding in the striatum and over its subregions (head of caudate and putamen). The investigator performing the ROI analyses needs to be unaware of the subject's demographic characteristics.80 Transverse/oblique slices are usually chosen for ROI definition, such as transaxial slices oriented along the orbitomeatal line, and the two slices corresponding to the highest right and left striatal uptake are positioned on summed images.81 Data evaluation must always consider relevant morphological information (by CT or MRI), especially in structural lesions in the basal ganglia and the reference structures that are chosen as ROI. Given that postmortem studies have shown a very low density of DAT and SERT in occipital cortices and the cerebellum,82–84 these reference regions with absent (or low) DAT density are taken to indicate nondisplaceable DAT activity and are used to assess nonspecific binding. Quantitative studies that are coregistered to the template or performed with anatomically adjusted ROIs (using templates or MRI overlay techniques) or on a pixelwise basis, in which they self-correspond exactly to the three-dimensional ROI map, ensure that the results are highly observer-independent, precise, and reproducible, because of the automated processing.85 Striatal dopamine ROI areas for monoamine transporters, mainly reflecting SERT,82 are visually positioned on the summed transversal slices of the hypothalamus/midbrain (including the raphe nuclei, substantia nigra and colliculi), the thalamus and the medial prefrontal area at the striatal level. These areas have been identified through magnetic resonance imaging scans using a reference atlas.86 If available, ROI definition may be based on individual morphology, as obtained by image fusion with MRI, which is particularly important when low specific binding is expected (e.g. in cases of severe loss or blockade of the DAT).

DAT binding potential (BP), corresponding to the product of the free receptor density and affinity, is calculated as the ratio of striatal specific binding to steady-state free unmetabolized plasma tracer concentration.87 Given that each tracer attains a state of equilibrium in the striatal and occipital areas at a certain time after its injection, the ratio point at this time is used as an estimate for the BP.88 The specific DAT BP in the basal ganglia is calculated as the difference between striatal activity and the reference region, i.e. the occipital activity (OA) at equilibrium. The ratio of the total binding in the striatum minus the nondisplaceable binding in the OA divided by the OA reflects the specificto-nondisplaceable binding.

Before proceeding with imaging quantification, it is necessary to be aware of possible technical artifacts (pitfalls) such as head motion, attenuation artifacts and technical artifacts due to gamma camera problems.

Before interpreting the data, possible interaction with concomitant medications must be taken into account and it is essential to objectively assess the semi-quantification of striatal DAT binding. Inter-individual quantitative results are based on comparisons between specific DAT BP obtained in the patients and normal controls that are preferably age-matched (thereby avoiding over-interpretation: age-dependency is a known pitfall/source of error). Age-specific sensitivity and specificity of DAT SPECT imaging for differentiating patients with PD from healthy subjects is greater than when there is no age matching.89

It is also important to utilize the same type of camera and the same image evaluation technique. If age-matched data comparisons are available, it is recommendable to use analytical approaches based on stereotactic normalization, in order to determine abnormalities of DAT BP in an observer-independent manner. Moreover, it is important to establish a control group for the central database, thus allowing comparative calculations for the different imaging protocols.

Limitations of DAT imaging Limitations of DAT imaging

In routine clinical practice, even experienced neurologists have difficulty in differentiating early-stage PD from atypical Parkinsonian syndromes (APS).90,91 The accuracy of the clinical diagnoses of PD, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), cortical basal degeneration (CBD) and vascular Parkinsonism is imperfect and error rates can be as high as 25%.4 Although DAT imaging is the best parameter for evaluating dopamine neuron loss and differentiating between Parkinsonism and non-Parkinsonism, it may not be useful for differentiating PD from APS, PSP, MSA, CBD and drug-induced Parkinsonism.92,93 Postsynaptic dopamine receptor imaging using PET-SPECT or MR-based techniques such as diffusion weighted imaging or volumetry are more likely to contribute to a differential diagnosis between PD/APS and MSA/PSP than is DAT-SPECT imaging.94,95 Although there is controversy in the literature, merged imaging between DAT and MRI may be helpful for differentiating between PSP and PD in routine clinical practice.96 Combining this with D2 receptor imaging can differentiate between MSA and PD,97 because each type of Parkinsonian syndrome has its own physio-pathology and rates of dopamine neuron loss and post-synaptic receptor compensation in the striatum (caudate and putamen). In contrast, the distinction between CBD and other Parkinsonian syndromes by means of DAT and D2 receptor imaging is limited.95

DAT neuroimaging and PD diagnosis

The most-used radiotracer is [123I] β-CIT. In an evaluation of 113 PD patients, there was a good correlation between DAT density loss and PD symptoms (Unified Parkinson's Disease Rating Scale, UPDRS), and the decrease in signal ranged from 35% in a Hoehn-Yahr (H&Y) stage I patient to 75% in an H&Y stage V patient.92 Using [123I] β-CIT, a multicenter study found sensitivity of 98% and specificity of 83% for PD diagnosis, in differentiation from PSP and essential tremor (ET).39 A six-month follow-up study on 35 suspected PD patients found that [123I] β-CIT was more accurate (sensitivity 0.92; specificity 1.00) than the clinical diagnosis (sensitivity 0.92; specificity 0.30).98 A retrospective study on 72 early-stage untreated Parkinsonian syndrome (PS) patients revealed lower caudate nucleus binding ratios and higher putamen binding ratios among cases that were later diagnosed or rediagnosed as APS and IPD, thus showing that striatal involvement appeared to have little predictive value in these individual cases.99

In a study on the fast pharmacokinetic radioligand FP-CIT, 95% sensitivity and 93% specificity for differentiating between Parkinsonism and ET were found.100 This provides further evidence that FP-CIT provides robust estimates of disease severity, correlating with the duration of PD.101 However, variability in uptake values suggests that factors other than nigrostriatal degeneration may contribute towards disease severity. There is a correlation with bradykinesia but not with tremor, thus suggesting that the origin of tremors is beyond the DAT system. Another study comparing 18 PD patients with or without the Parkinsonism gene has now found that Parkinsonism-related disease may be associated with a higher degree of nigrostriatal impairment, independent of the clinical severity of the disease, and more symmetrical involvement than in non-Parkinsonian early-onset disease.102

Imaging studies using the technetium-labeled radioligand TRODAT-1 have found good correlation between the H&Y and UPDRS scales.103 This method is useful for early PD detection,104 and it has been suggested that it may be useful for differential diagnosis of some kinds of movement disorders.105 Results from a crossover study have suggested that [99mTc]-TRODAT-1 SPECT may provide a reliable alternative to [18F]-dopa PET in the evaluation of clinical PD patients.106 A reproducibility study using TRODAT-1 scans from 20 PD patients showed excellent test-retest reliability in evaluating PD progression.107 The diagnostic accuracy of [99mTc]-TRODAT-1 SPECT showed sensitivity of 0.79 and specificity of 0.92 in distinguishing 29 patients with early PD from 38 healthy volunteers.108 Furthermore, in a sample of patients with different stages of PD and healthy controls, another research group found good concordance when visual interpretation of [99mTc]-TRODAT-1 SPET images was used to evaluate the presence of PD (sensitivity 0.98 and specificity 0.86).109 Using age-matched PD patients and healthy controls, Weng et al. (2004) showed that [99mTc]-TRODAT-1 SPECT has a high sensitivity and specificity for measuring the decrement of DAT in PD patients.110 A cross-sectional study on 96 early-stage patients comparing [123I] FP-CIT and [99mTc] TRODAT-1, found sensitivity/specificity of 0.95/0.86 and 0.92/0.70, respectively.111

There are only a few studies in the literature involving other tropane derivatives, and so far only preliminary experiences have been presented. [18F] β-CFT was found to be a sensitive marker for dopaminergic dysfunction that could be used in diagnoses, disease severity assessments and patient follow-up.47 Reduced striatal dopamine transporter binding assessed by [123I]IPT in patients with early Parkinson's disease demonstrates the potential of this method to detect preclinical disease.112 Prunier et al. (2003), studying nonhuman primates chronically treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine according to a regimen that consistently produces a progressive Parkinsonian state, have shown that [123I]-PE2I SPECT was able to detect presymptomatic lesions of nigrostriatal neurons and suggested that this method could now be used clinically for early diagnosis of Parkinson's disease.113

DISCUSSION

Several molecular imaging techniques have been developed for diagnosing and evaluating PD progression. DAT radiotracers seem to be the best markers for identifying PD patients, with high sensitivity and specificity. DAT reduction correlates with dopamine neurons loss in the substantia nigra and striatum.26,114,115 This is why the striatal concentration of DAT, preferentially putamen DAT, is a highly sensitive parameter for detecting early phases of PD.39 DAT ligands are well-established markers that are useful in evaluating changes in presynaptic DAT sites in vivo and in vitro.

The PET isotopes and [123I] are produced in cyclotrons and have limited availability and relatively high cost, thus limiting the availability of such DAT tracers for routine application in DAT imaging106 Studies have reported that [99mTc]-TRODAT-1 SPECT is useful.105,116 The ready availability and ease of use of [99mTc] agents using a modified TRODAT-1 preparation kit117 are advantages that provide a powerful incentive for their routine use in clinical studies.

Although PD is characterized by selective loss of dopamine neurons in the basal ganglia and substantia nigra, these are not the only brain changes occurring in these patients’ brains. Several other changes leading to neuro-psychological deficits cannot be explained by dopamine loss.118 In a study on 32 PD patients using [123I] β-CIT, it was found that although striatal uptake was correlated with clinical severity, the annual percentage loss of striatal uptake did not correlate with the annual loss in measurements of clinical function.119 On the other hand, there was a non-significant difference in progression rate across three scans obtained over a five-year period among 24 early PD patients.120 In a longitudinal study assessing PD progression, the annual rate of reduction of striatal DAT uptake was approximately 6 to 13% in PD patients, compared with 0 to 2.5% in healthy controls, which was in line with the results from [18F] dopa-PET studies.121–123 However, most of these studies were conducted among patients with advanced PD.124 Furthermore, DAT tracers present certain problems in evaluating PD progression, because of changes in the DAT system (up or downregulation) induced by drug treatment, and this method has not been fully validated as an outcome measurement for trials on PD treatments. Future studies should focus on the early stages of PD, i.e. the time when the diagnosis is uncertain and DAT imaging techniques would be more useful.

As indicated above, DAT imaging can only show the dopamine neuron degeneration process, which indeed is the main physiopathology of PD as far as the early stages of the disease are concerned. In fact, few studies have evaluated the usefulness of DAT imaging for providing clear diagnosis in the early stages of PD. Further studies examining the specificity of the diagnosis of PD using DAT imaging are needed. Nevertheless, early dopamine neuron loss can easily be detected by means of SPECT and PET DAT quantification. Early dopamine neuron loss detection enables interventions for minimizing and stabilizing these progressions by means of neuroprotection treatments. Although neuroprotective therapy is still controversial and so far non-existent for PD, several strategies have been studied and it is hoped that they will soon be in use. These strategies include exposure to enriched environments (a combination of exercise, social interaction and learning);125 the use of MAO-inhibitors;126 L-dopa coadministered with the adenosine A2A receptor agonist;127 and gene neuroprotective therapy models (neurotrophic factors, i.e. genes to prevent apoptosis or detoxify free radical species that protect and restore the nigrostriatal pathway).128

Molecular imaging in Brazil

PET isotopes and SPECT 123I are produced in cyclotrons and have limited availability, relatively short half-life and high cost, thereby limiting the accessibility of DAT tracers.106 In Brazil, the use of those cyclotron-generated radioligands is limited by the volume of tracer production, which is restricted to certain government institutions.129 This restriction limits the availability of radiotracers and, more importantly, inhibits the development of the radiopharmacy laboratories and radiochemists that are fundamental for the advance of molecular imaging in Brazil.130

The advantage of tracers such as [99mTc] TRODAT-1 is the ready availability and ease manipulation of 99mTc using a modified preparation of TRODAT-1 by means of a kit.117 In Brazil, some animal studies using [99mTc] TRODAT-1 have been conducted.131 Our group performed the first studies on humans using this tracer and obtained encouraging results. The data so far suggests that this tracer is an uncomplicated and reliable tool for routine clinical studies and favors its general introduction. As noted, the application of these methods in our country is very recent. Today, the first neuroimaging pilot study on humans, using TRODAT-1 and SPECT, is underway in Brazil for evaluating PD patients.132 Several other research protocols using [99mTc] TRODAT-1 and SPECT may be developed to investigate DAT in neuropsychiatric disorders involving the dopaminergic system, such as early onset Parkinson's disease, attention deficit and hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) and schizophrenia.

CONCLUSIONS

DAT imaging can be used in the differential diagnosis between Parkinsonian and non-Parkinsonian syndromes and in cases of uncertainty involving essential tremor. The high sensitivity and specificity of SPECT semi-quantitative images makes this method a useful tool in the early clinical PD evaluation and in preclinical screening for asymptomatic patients. At the present moment, DAT imaging is the best biomarker for evaluating dopamine neuron loss, which is responsible for most of the motor symptoms in PD patients.

TRODAT-1 is a SPECT tracer that is easy to manipulate. Recent data suggest that it can be safely used in Brazil.131–133 Although the current availability is restricted to research centers, it is expected that it will soon be available for routine clinical use.

Acknowledgements:

R.A. Bressan is supported by a PRO-DOC research grant from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). M.C. Shih is supported by a PhD scholarship from CAPES and Instituto Israelita de Ensino e Pesquisa Albert Einstein.

Ming Chi Shih, MD. Laboratório Interdisciplinar de Neuroimagem e Cognição (LiNC), Universidade Federal de São Paulo; and Instituto Israelita de Ensino e Pesquisa (IIEP), Hospital Israelita Albert Einstein (HIAE), São Paulo, Brazil.

Marcelo Queiroz Hoexter, MD. Laboratório Interdisciplinar de Neuroimagem e Cognição (LiNC), Universidade Federal de São Paulo, São Paulo, Brazil.

Luiz Augusto Franco de Andrade MD, PhD. Instituto Israelita de Ensino e Pesquisa (IIEP), Hospital Israelita Albert Einstein (HIAE), São Paulo, Brazil.

Rodrigo Affonseca Bressan, MD, PhD. Laboratório Interdisciplinar de Neuroimagem e Cognição (LiNC), Universidade Federal de São Paulo, São Paulo, Brazil.

Sources of funding: Not declared

Laboratório Interdisciplinar de Neuroimagem e Cognição (LiNC), Universidade Federal de São Paulo and Instituto Israelita de Ensino e Pesquisa (IIEP), Hospital Israelita Albert Einstein (HIAE), São Paulo, Brazil
==== Refs
REFERENCES

1 Gelb DJ Oliver E Gilman S Diagnostic criteria for Parkinson disease Arch Neurol 1999 56 1 33 39 9923759
2 Dawson TM Dawson VL Rare genetic mutations shed light on the pathogenesis of Parkinson disease J Clin Invest 2003 111 2 145 151 12531866
3 Tanner CM Goldman SM Epidemiology of Parkinson's disease Neurol Clin 1996 14 2 317 335 8827174
4 Hughes AJ Daniel SE Kilford L Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 1992 55 3 181 184 1564476
5 Calne DB Snow BJ Lee C Criteria for diagnosing Parkinson's disease Ann Neurol 1992 32 Suppl S125 S127 1510370
6 Hansen L Salmon D Galasko D The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity Neurology 1990 40 1 1 8
7 Gibb WR Scaravilli F Michund J Lewy bodies and subacute sclerosing panencephalitis J Neurol Neurosurg Psychiatry 1990 53 8 710 711 2170586
8 Ishikawa A Takahashi H Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism J Neurol 1998 245 11 Suppl 3 P4 P9 9808334
9 Hughes AJ Daniel SE Blankson S Lees AJ A clinicopatho-logic study of 100 cases of Parkinson's disease Arch Neurol 1993 50 2 140 148 8431132
10 Agid Y Parkinson's disease: pathophysiology Lancet 1991 337 8753 1321 1324 1674304
11 Brooks DJ PET studies on the early and differential diagnosis of Parkinson's disease Neurology 1993 43 12 Suppl 6 S6 16
12 Bressan RA Erlandsson K Jones HM Mulligan RS Ell PJ Pilowsky LS Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study J Clin Psychopharmacol 2003 23 1 5 14 12544369
13 Frost JJ Rosier AJ Reich SG Positron emission tomo-graphic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease Ann Neurol 1993 34 3 423 431 8363363
14 Guttman M Burkholder J Kish SJ [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold Neurology 1997 48 6 1578 1583 9191769
15 Innis RB Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease Eur J Nucl Med 1994 21 1 1 5 8088279
16 Marek KL Seibyl JP Zoghbi SS [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease Neurology 1996 46 1 231 237 8559382
17 Seibyl JP Marek K Sheff K Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients J Nucl Med 1998 39 9 1500 1508 9744331
18 Booij J Tissingh G Winogrodzka A van Royen EA Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism Eur J Nucl Med 1999 26 2 171 182 9933352
19 Innis RB Seibyl JP Scanley BE Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease Proc Natl Acad Sci USA 1993 90 24 11965 11969 8265656
20 Iversen LL Role of transmitter uptake mechanisms in synaptic neurotransmission Br J Pharmacol 1971 41 4 571 591 4397129
21 Nirenberg MJ Vaughan RA Uhl GR Kuhar MJ Pickel VM The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons J Neurosci 1996 16 2 436 447 8551328
22 Giros B el Mestikawy S Godinot N Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter Mol Pharmacol 1992 42 3 383 390 1406597
23 Donovan DM Vandenbergh DJ Perry MP Human and mouse dopamine transporter genes: conservation of 5’-flanking sequence elements and gene structures Brain Res Mol Brain Res 1995 30 2 327 335 7637582
24 Vandenbergh DJ Persico AM Hawkins AL Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR Genomics 1992 14 4 1104 1106 1478653
25 Ciliax BJ Heilman C Demchyshyn LL The dopamine transporter: immunochemical characterization and localization in brain J Neurosci 1995 15 3 Pt 1 1714 1723 7534339
26 Kish SJ Shannak K Hornykiewicz O Uneven pattern of dopa-mine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications N Engl J Med 1988 318 14 876 880 3352672
27 Batchelor M Schenk JO Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine J Neurosci 1998 18 24 10304 10309 9852568
28 Chen N Reith ME Structure and function of the dopamine transporter Eur J Pharmacol 2000 405 1-3 329 339 11033338
29 Melikian HE Buckley KM Membrane trafficking regulates the activity of the human dopamine transporter J Neurosci 1999 19 18 7699 7710 10479674
30 Bressan RA Crippa JA The role of dopamine in reward and pleasure behaviour-review of data from preclinical research Acta Psychiatr Scand Suppl 2005 427 14 21
31 Fowler JS Volkow ND Wolf AP Mapping cocaine binding sites in human and baboon brain in vivo Synapse 1989 4 4 371 377 2557686
32 Volkow ND Ding YS Fowler JS A new PET ligand for the dopamine transporter: studies in the human brain J Nucl Med 1995 36 12 2162 2168 8523098
33 Ma SY Ciliax BJ Stebbins G Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra J Comp Neurol 1999 409 1 25 37 10363709
34 Scherman D Desnos C Darchen F Pollak P Javoy-Agid F Agid Y Striatal dopamine deficiency in Parkinson's disease: role of aging Ann Neurol 1989 26 4 551 557 2817829
35 van Dyck CH Seibyl JP Malison RT Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT J Nucl Med 1995 36 7 1175 1181 7790941
36 Uhl GR Neurotransmitter transporters (plus): a promising new gene family Trends Neurosci 1992 15 7 265 268 1381123
37 Wilson JM Levey AI Rajput A Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease Neurology 1996 47 3 718 726 8797470
38 Niznik HB Fogel EF Fassos FF Seeman P The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus J Neurochem 1991 56 1 192 198 1987318
39 Madras BK Gracz LM Fahey MA Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain Synapse 1998 29 2 116 127 9593102
40 Seibyl JP Marek KL Quinlan D Decreased single-photon emission computed tomographic [123I] beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease Ann Neurol 1995 38 4 589 598 7574455
41 A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group Neurology 2000 55 10 1540 1547 11094111
42 Leenders KL Palmer AJ Quinn N Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography J Neurol Neurosurg Psychiatry 1986 49 8 853 860 3091770
43 Brooks DJ Ibanez V Sawle GV Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy Ann Neurol 1990 28 4 547 555 2132742
44 Seibyl JP Single-photon emission computed tomography of the dopamine transporter in parkinsonism J Neuroimaging 1999 9 4 223 228 10540602
45 Ritz MC Cone EJ Kuhar MJ Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study Life Sci 1990 46 9 635 645 2308472
46 Logan J Fowler JS Volkow ND Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects J Cereb Blood Flow Metab 1990 10 5 740 747 2384545
47 Telang FW Volkow ND Levy A Distribution of tracer levels of cocaine in the human brain as assessed with averaged [11C] cocaine images Synapse 1999 31 4 290 296 10051110
48 Rinne JO Ruottinen H Bergman J Haaparanta M Sonninen P Solin O Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease J Neurol Neurosurg Psychiatry 1999 67 6 737 741 10567489
49 Rinne JO Bergman J Ruottinen H Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease Synapse 1999 31 2 119 124 10024008
50 Madras BK Spealman RD Fahey MA Neumeyer JL Saha JK Milius RA Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane Mol Pharmacol 1989 36 4 518 524 2811854
51 Morris ED Babich JW Alpert NM Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT Synapse 1996 24 3 262 272 8923667
52 Haaparanta M Bergman J Laakso A Hietala J Solin O [18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats Synapse 1996 23 4 321 327 8855517
53 Brownell AL Elmaleh DR Meltzer PC Cocaine congeners as PET imaging probes for dopamine terminals J Nucl Med 1996 37 7 1186 1192 8965196
54 Gatley SJ Ding YS Volkow ND Chen R Sugano Y Fowler JS Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine Eur J Pharmacol 1995 281 2 141 149 7589201
55 Laruelle M Giddings SS Zea-Ponce Y Methyl 3 beta-(4-[125I] iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under “physiological” conditions J Neurochem 1994 62 3 978 986 8113817
56 Brucke T Kornhuber J Angelberger P Asenbaum S Frassine H Podreka I SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT Binding kinetics in the human brain J Neural Transm Gen Sect 1993 94 2 137 146 8110440
57 Laruelle M Wallace E Seibyl JP Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects J Cereb Blood Flow Metab 1994 14 6 982 994 7929662
58 Kuikka JT Akerman K Bergstrom KA Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain Eur J Nucl Med 1995 22 7 682 686 7498231
59 Antonini A Moresco RM Gobbo C The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT Neurol Sci 2001 22 1 47 48 11487195
60 Tissingh G Booij J Bergmans P Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease J Nucl Med 1998 39 7 1143 1148 9669384
61 Booij J Speelman JD Horstink MW Wolters EC The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism Eur J Nucl Med 2001 28 3 266 272 11315592
62 Lundkvist C Halldin C Ginovart N Swahn CG Farde L [18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter Nucl Med Biol 1997 24 7 621 627 9352532
63 Chaly T Dhawan V Kazumata K Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography Nucl Med Biol 1996 23 8 999 1004 9004288
64 Abi-Dargham A Gandelman MS DeErausquin GA SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT J Nucl Med 1996 37 7 1129 1133 8965183
65 Madras BK Meltzer PC Liang AY Elmaleh DR Babich J Fischman AJ Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain Synapse 1998 29 2 93 104 9593100
66 Madras BK Gracz LM Meltzer PC Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain Synapse 1998 29 2 105 115 9593101
67 Fischman AJ Bonab AA Babich JW Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters Synapse 1998 29 2 128 141 9593103
68 Elmaleh DR Fischman AJ Shoup TM Preparation and biological evaluation of iodine-125-IACFT: a selective SPECT agent for imaging dopamine transporter sites J Nucl Med 1996 37 7 1197 1202 8965198
69 Emond P Garreau L Chalon S Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4’-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3’,4’-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter J Med Chem 1997 40 9 1366 1372 9135033
70 Chalon S Garreau L Emond P Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4’-methylphenyl n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter J Pharmacol Exp Ther 1999 291 2 648 654 10525084
71 Hall H Halldin C Guilloteau D Visualization of the dopa-mine transporter in the human brain postmortem with the new selective ligand [125I]PE2I Neuroimage 1999 9 1 108 116 9918732
72 Guilloteau D Emond P Baulieu JL Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4’-m ethylph enyl)nortropane (PE2I) Nucl Med Biol 1998 25 4 331 337 9639293
73 Poyot T Conde F Gregoire MC Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa J Cereb Blood Flow Metab 2001 21 7 782 792 11435790
74 Kuikka JT Tupala E Bergstrom KA Hiltunen J Tiihonen J Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects Eur J Nucl Med 1999 26 11 1486 1488 10552092
75 Repo E Kuikka JT Bergstrom KA Karhu J Hiltunen J Tiihonen J Dopamine transporter and D2-receptor density in late-onset alcoholism Psychopharmacology (Berl) 1999 147 3 314 318 10639691
76 Choi SR Kung MP Plossl K Meegalla S Kung HF An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1 Nucl Med Biol 1999 26 4 461 466 10382851
77 Acton PD Kushner SA Kung MP Mozley PD Plossl K Kung HF Simplified reference region model for the kinetic analysis of [99mTc]TRODAT-1 binding to dopamine transporters in nonhuman primates using single-photon emission tomography Eur J Nucl Med 1999 26 5 518 526 10382097
78 Kao PF Tzen KY Yen TC The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease Nucl Med Commun 2001 22 2 151 154 11258401
79 Lee CS Samii A Sossi V In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann Neurol 2000 47 4 493 503 10762161
80 Tatsch K Asenbaum S Bartenstein P European Association of Nuclear Medicine procedure guidelines for brain neurotrans-mission SPET using (123)I-labelled dopamine D(2) transporter ligands Eur J Nucl Med Mol Imaging 2002 29 10 BP30 BP35 12436496
81 Laine TP Ahonen A Torniainen P Dopamine transporters increase in human brain after alcohol withdrawal Mol Psychiatry 1999 4 2 189 191 104-5 10208452
82 Laruelle M Vanisberg MA Maloteaux JM Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites Biol Psychiatry 1988 24 3 299 309 2969755
83 Palacios JM Camps M Cortes R Probst A Mapping dopa-mine receptors in the human brain J Neural Transm Suppl 1988 27 227 235 2969952
84 De Keyser J Ebinger G Vauquelin G Evidence for a widespread dopaminergic innervation of the human cerebral neocortex Neurosci Lett 1989 104 3 281 285 2530474
85 Schwarz J Storch A Koch W Pogarell O Radau PE Tatsch K Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline J Nucl Med 2004 45 10 1694 1697 15471835
86 Talairach J Tournoux P Co-planar stereotaxic atlas of the human brain New York Thieme 1988
87 Schneier FR Liebowitz MR Abi-Dargham A Zea-Ponce Y Lin SH Laruelle M Low dopamine D(2) receptor binding potential in social phobia Am J Psychiatry 2000 157 3 457 459 10698826
88 Abi-Dargham A Gandelman MS DeErausquin GA SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT J Nucl Med 1996 37 7 1129 1133 8965183
89 Weng YH Yen TC Chen MC Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects J Nucl Med 2004 45 3 393 401 15001678
90 Lingford-Hughes A There is more to dopamine than just pleasure. Commentary on Volkow et al. ‘Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies’ Behav Pharmacol 2002 13 5-6 367 370 12394412
91 Poewe W Wenning G The differential diagnosis of Parkinson's disease Eur J Neurol 2002 9 Suppl 3 23 30
92 Brucke T Asenbaum S Pirker W Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy J Neural Transm Suppl 1997 50 9 24 9120429
93 Plotkin M Amthauer H Klaffke S Combined 123IFP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients J Neural Transm 2005 112 5 677 692 15375677
94 Seppi K Schocke MF Esterhammer R Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy Neurology 2003 60 6 922 927 12654954
95 Schreckenberger M Hagele S Siessmeier T The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism Eur J Nucl Med Mol Imaging 2004 31 8 1128 1135 15042325
96 Antonini A Benti R De Notaris R 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy Neurol Sci 2003 24 3 149 150 14598060
97 Knudsen GM Karlsborg M Thomsen G Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy Eur J Nucl Med Mol Imaging 2004 31 12 1631 1638 15583914
98 Jennings DL Seibyl JP Oakes D Eberly S Murphy J Marek K (123I) beta-CIT and single-photon emission computed tomo-graphic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis Arch Neurol 2004 61 8 1224 1229 15313838
99 Stoffers D Booij J Bosscher L Winogrodzka A Wolters EC Berendse HW Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease Eur J Nucl Med Mol Imaging 2005 32 6 689 695 15682332
100 Benamer TS Patterson J Grosset DG Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group Mov Disord 2000 15 3 503 510
101 Benamer HT Patterson J Wyper DJ Hadley DM Macphee GJ Grosset DG Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake Mov Disord 2000 15 4 692 698 10928580
102 Varrone A Pellecchia MT Amboni M Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease Neurology 2004 63 11 2097 2103 15596756
103 Weng YH Yen TC Chen MC Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects J Nucl Med 2004 45 3 393 401 15001678
104 Huang WS Lin SZ Lin JC Wey SP Ting G Liu RS Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging J Nucl Med 2001 42 9 1303 1308 11535717
105 Kanyo B Argyelan M Dibo G Dopamintranszportervizsgálatok egyfoton-emissziós komputertomográfiával (SPECT) mozgászavarokkal járó kórképekben. [Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders] Ideggyogy Sz 2003 56 7-8 231 240 12971118
106 Huang WS Chiang YH Lin JC Chou YH Cheng CY Liu RS Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients J Nucl Med 2003 44 7 999 1005 12843212
107 Hwang WJ Yao WJ Wey SP Ting G Reproducibility of 99mTcTRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease J Nucl Med 2004 45 2 207 213 14960637
108 Chou KL Hurtig HI Stern MB Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease Parkinsonism Relat Disord 2004 10 6 375 379 15261880
109 Huang WS Lee MS Lin JC Usefulness of brain 99mTcTRODAT-1 SPET for the evaluation of Parkinson's disease Eur J Nucl Med Mol Imaging 2004 31 2 155 161 15129696
110 Weng YH Yen TC Chen MC Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects J Nucl Med 2004 45 3 393 401 15001678
111 Van Laere K De Ceuninck L Dom R Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1 Eur J Nucl Med Mol Imaging 2004 31 8 1119 1127 15064872
112 Schwarz J Linke R Kerner M Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis Arch Neurol 2000 57 2 205 208 10681078
113 Prunier C Bezard E Montharu J Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT Neuroimage 2003 19 3 810 816
114 Kaufman MJ Madras BK Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum Synapse 1991 9 1 43 49 1796351
115 Wilson JM Levey AI Rajput A Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease Neurology 1996 47 3 718 726 8797470
116 Mozley PD Schneider JS Acton PD Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers J Nucl Med 2000 41 4 584 589 10768556
117 Choi SR Kung MP Plossl K Meegalla S Kung HF An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1 Nucl Med Biol 1999 26 4 461 466 10382851
118 Gibb WR Functional neuropathology in Parkinson's disease Eur Neurol 1997 38 Suppl 2 21 25
119 Marek K Innis R van Dyck C [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression Neurology 2001 57 11 2089 2094 11739831
120 Pirker W Holler I Gerschlager W Asenbaum S Zettinig G Brucke T Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT Mov Disord 2003 18 11 1266 1272 14639666
121 Pirker W Djamshidian S Asenbaum S Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study Mov Disord 2002 17 1 45 53 11835438
122 Chouker M Tatsch K Linke R Pogarell O Hahn K Schwarz J Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years Nucl Med Commun 2001 22 6 721 725 11403185
123 Staffen W Mair A Unterrainer J Trinka E Ladurner G Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT J Neural Transm 2000 107 5 543 552 11072750
124 Ravina B Eidelberg D Ahlskog JE The role of radiotracer imaging in Parkinson disease Neurology 2005 64 2 208 215 15668415
125 Faherty CJ Raviie Shepherd K Herasimtschuk A Smeyne RJ Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism Brain Res Mol Brain Res 2005 134 1 170 179 15790541
126 Riederer P Lachenmayer L Laux G Clinical applications of MAO-inhibitors Curr Med Chem 2004 11 15 2033 2043 15279566
127 Agnati LF Leo G Vergoni AV Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease Brain Res Bull 2004 64 2 155 164 15342103
128 Fraix V Thérapie génique et maladie de Parkinson. [Gene therapy for Parkinson's disease] Rev Med Interne 2004 25 7 524 527 15219371
129 Bressan RA Bigliani V Pilowsky LS Neuroimagem de receptores D2 de dopamina na esquizofrenia. [Neuroimaging of D2 dopamine receptors in schizophrenia] Rev Bras Psiquiatr 2001 23 Supl 1 SI46:SI64 SI49-SI64
130 Costa DC Oliveira JM Bressan RA PET e SPECT em neurologia e psiquiatria: do básico às aplicacöes clínicas. [PET and SPECT in Neurology and Psychiatry: From the basic to the clinical applications] Rev Bras Psiquiatr 2001 23 Supl 1 SI4:SI61 SI5-SI61
131 Shih MC Rodrigues GS Cuyumjian PR SPECT com [99mTc]-TRODAT-1; definição de protocolo de aquisição com marcador de transportador dopaminérgico Rev Imagem 2004 26 Suplemento 1 100 100 [abstract]
132 Shih MC Amaro E Goulart FO Striatal functional imaging [99mTc]-TRODAT-1 SPECT and spectroscopic from magnetic resonance study to evaluate dopamine neuron density J Nucl Med 2005 46 Suppl 5 215 215 [poster]
133 Shih MC Amaro E Jr Ferraz HB Neuroimaging of the Dopamine Transporter in Parkinson's Disease – First study using [99mTc]-TRODAT-1 and SPECT in Brazil Arq Neuropsiquiatr (in press)
